Wegovy pill prescriptions set a US weekly high as Lilly keeps its lead

Wegovy pill prescriptions in the United States reached 217,050 in the latest reporting week, according to media reports carried on Friday 30 October. That is a 4.2% weekly rise and the highest count since Novo Nordisk's oral semaglutide tablet came to market. The record is a demand marker for an approved peptide drug, not a sales figure. It lands as Eli Lilly widens its lead in GLP 1 medicines and as Novo lines up 26 obesity abstracts for ObesityWeek in Washington, and the report noted that none of the announcements contains new efficacy results.

Oral semaglutide demand sets a new weekly mark

The figure counts prescriptions for oral semaglutide, sold as the Wegovy pill, across one US reporting week. According to the ad hoc news report, the total climbed 4.2% from the week before to 217,050, the strongest reading since launch. The report did not name the data vendor behind the count. It also did not say how many scripts were first prescriptions and how many were refills. That gap matters. A refill and a new start weigh the same in a weekly total, yet they answer different questions. New starts show whether fresh patients are still arriving, while refills show whether people already on the tablet are staying with it. Without that split, the record confirms rising volume but not where the volume comes from.

Prescription counts are not revenue, and the report stressed that the number should not be read as a sales or earnings disclosure. Price, rebates and payer mix all sit between a filled script and a booked sale. Novo Nordisk shares rose 2.7% on Friday, but the report found no proven link between that gain and the prescription record. The underlying trend is not new. As Peptide Exchange reported, a JAMA Network Open research letter found that new starts on the pill briefly passed the semaglutide injection by March 2026, while tirzepatide stayed ahead. The latest weekly high suggests that early pull has held into the autumn. The next few weekly counts will show whether the climb continues or levels off.

Lilly keeps the lead in GLP 1 competition

The record arrived in the same week that Reuters reported Eli Lilly widening its lead over Novo Nordisk in GLP 1 medicines, a picture backed by Lilly's quarterly report and its raised revenue guidance for 2026. The main engine is tirzepatide, a weekly injection. As we reported, tirzepatide injections brought in about 16.1 billion dollars in Lilly's latest results. Lilly's own daily pill, the non peptide GLP 1 agonist orforglipron sold as Foundayo, nearly doubled its revenue but still missed Wall Street forecasts by 44 million dollars. That leaves two separate contests running side by side. One is the race among GLP 1 pills. The other is the overall market for obesity and diabetes drugs, where injections still carry most of the money.

A prescription record shows that more people are filling the tablet, not that Novo Nordisk is closing the gap with Lilly.

Both trends can hold at the same time. A prescription record shows that more people are filling the tablet, not that Novo Nordisk is closing the gap with Lilly. For a pipeline tracker, the useful question is narrower: can oral semaglutide keep its early position among GLP 1 pills as orforglipron reaches new markets? Orforglipron has already won a positive opinion from the European Medicines Agency's human medicines committee. Novo's tablet, by contrast, has stalled in India, where expert reviewers asked for local data. The same caution about cause and effect applies here. The report could not connect the Reuters coverage to Novo's Friday share move, and Wegovy pill prescriptions alone cannot show whether patients are picking one pill over another. That needs head to head or switching data, and none has been published.

ObesityWeek abstracts and the liver slate

Novo Nordisk said on Thursday 29 October that it will present 26 abstracts on its obesity portfolio at ObesityWeek, which runs from 14 to 17 November in Washington, D.C. The slate covers CagriSema analyses, Wegovy data from real world treatment and research into obesity in children. It also includes experience with the Wegovy pill outside controlled trials. Real world data can show how a drug behaves in everyday care, with broader patients and looser follow up. It cannot replace a randomised comparison, because the people who start and stay on a drug in practice differ from those who do not. The announcement itself contains no new efficacy results, so it gives no grounds to infer any added benefit for the tablet.

A day earlier, on Wednesday 28 October, the company announced a separate set of 12 abstracts for The Liver Meeting, scheduled for 5 to 9 November. That programme covers clinical and care related semaglutide data, along with work on efruxifermin, an investigational drug that is not on our peptide board. As with the ObesityWeek abstracts, the company did not present the liver slate as new efficacy news. For readers tracking Wegovy pill prescriptions, the November meetings are a volume event first. The number of posters says little on its own. What will matter is whether any of them answers an open question with a planned analysis, such as how long people stay on the tablet, or how its results compare with the weekly injection.

The CagriSema REDEFINE 1 number and its limits

The only hard efficacy figure in the current news flow is a CagriSema REDEFINE 1 analysis. CagriSema is Novo's weekly combination of the amylin analog cagrilintide with semaglutide. The post hoc analysis of the Phase 3 trial, published on 20 October, reported average weight loss of 25.0% at 68 weeks among women who stayed on treatment, against 3.0% on placebo. Our earlier report on the REDEFINE 1 subgroups set out the main limit. The trial was not designed in advance to compare menopause stages, so the split cannot be read as a general treatment result. Counting only people who stayed on the drug also tends to give a larger number than an analysis that keeps everyone who started.

None of this changes CagriSema's position on our board, where it remains filed with regulators. The coming readouts at ObesityWeek should be judged on more than the size of the weight loss. Readers should check which patients were studied, what the comparator was and whether the analysis was planned before the data were unblinded. A result that clears all three tests carries more weight than a larger number from an after the fact cut. The same standard applies to the Wegovy pill presentations. A durable step forward would be a clearly shown added benefit in a planned analysis, not a busier conference schedule. Until then, the record in Wegovy pill prescriptions is the firmest new data point for Novo this week.

Conclusion

Wegovy pill prescriptions hit a US weekly high of 217,050, a clear sign that demand for oral semaglutide is still rising. The count measures uptake, not sales, and it does not change Lilly's lead in GLP 1 competition. ObesityWeek and The Liver Meeting will add volume in November, but the company has not framed either slate as new efficacy news. The next real test for the tablet is planned data on persistence and comparison with injections. This story is research coverage, not medical advice.